AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

AbCellera's AI-driven drug discovery model hasn't translated into meaningful growth. Click here to read an analysis of ABCL ...

Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company entered into a multi-year agreement with Modella AI.

Democratizing Artificial Intelligence in Pre-Clinical Drug Discovery While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration ...

One of the first and most promising uses scientists envision for the rapidly evolving technology of quantum computing is a new approach to drug development. A quantum computer could, in theory ...

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development.

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to signals of drug activity, William Blair said, though the analysts pointed to ...

Chou et al. developed α-RgIA analogues incorporating methylene thioacetal bonds to enhance peptide stability and potency against human α9α10 nicotinic acetylcholine receptors (nAChRs), a promising non ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout. Altimmune’s dual GLP-1/glucagon agonist ...